Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705108 | 0.87 | IDH1 (0.46) | SCN9ASCN10AHCRTR2SCN7AKCNH2 | |
| SCHEMBL4287221 | 0.80 | REN (0.42) | HCRTR2SCN7AKCNH2 | |
| SCHEMBL27204297 | 0.79 | HCRTR2 (0.41) | SCN9AHCRTR2SCN7AKCNH2HCRTR1 | |
| SCHEMBL27158488 | 0.79 | HCRTR2 (0.41) | SCN9AHCRTR2SCN7AKCNH2HCRTR1 | |
| SCHEMBL4283292 | 0.79 | SCN9A (0.44) | SCN9ASCN10AHCRTR2SCN7AKCNH2 | |
| SCHEMBL3493424 | 0.77 | LTA4H (0.52) | SCN9ASCN10AKCNH2 | |
| SCHEMBL4287415 | 0.76 | REN (0.39) | — | |
| SCHEMBL4287596 | 0.76 | CA1 (0.41) | HCRTR2KCNH2HCRTR1HTR1ALOXL2 | |
| SCHEMBL4288512 | 0.75 | LTA4H (0.52) | — | |
| SCHEMBL4979175 | 0.75 | LTA4H (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885HCRTR2 3136/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885HCRTR2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.